Purification of Emu IgY for Therapeutic and Diagnostic Use Based on Monoclonal Secondary Antibodies Specific to Emu IgY
The emu is the second largest ratite; thus, their sera and egg yolks, obtained after immunization, could provide therapeutic and diagnostically important immunoglobulins with improved production efficiency. Reliable purification tools are required to establish a pipeline for supplying practical emu-derived antibodies, the majority of which belongs to the immunoglobulin Y (IgY) class. Therefore, we generated a monoclonal secondary antibody specific to emu IgY. Initially, we immunized an emu with bovine serum albumin multiply haptenized with 2,4-dinitrophenyl (DNP) groups. Polyclonal emu anti-DNP antibodies were partially purified using conventional precipitation method and used as antigen for immunizing a BALB/c mouse. Splenocytes were fused with myeloma cells and a hybridoma clone secreting a desirable secondary antibody (mAb#2-16) was established. The secondary antibody bound specifically to emu-derived IgY, distinguishing IgYs from chicken, duck, ostrich, quail, and turkey, as well as human IgGs. Affinity columns immobilizing the mAb#2-16 antibodies enabled purification of emu IgY fractions from sera and egg yolks via simple protocols, with which we succeeded in producing IgYs specific to the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein with a practical binding ability. We expect that the presented purification method, and the secondary antibody produced in this study, will facilitate the utilization of emus as a novel source of therapeutic and diagnostic antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Biological & pharmaceutical bulletin - 45(2022), 8 vom: 01., Seite 1022-1026 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamaki, Kouya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.08.2022 Date Revised 02.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1248/bpb.b22-00220 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344285766 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344285766 | ||
| 003 | DE-627 | ||
| 005 | 20231226022420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1248/bpb.b22-00220 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344285766 | ||
| 035 | |a (NLM)35908885 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamaki, Kouya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Purification of Emu IgY for Therapeutic and Diagnostic Use Based on Monoclonal Secondary Antibodies Specific to Emu IgY |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2022 | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The emu is the second largest ratite; thus, their sera and egg yolks, obtained after immunization, could provide therapeutic and diagnostically important immunoglobulins with improved production efficiency. Reliable purification tools are required to establish a pipeline for supplying practical emu-derived antibodies, the majority of which belongs to the immunoglobulin Y (IgY) class. Therefore, we generated a monoclonal secondary antibody specific to emu IgY. Initially, we immunized an emu with bovine serum albumin multiply haptenized with 2,4-dinitrophenyl (DNP) groups. Polyclonal emu anti-DNP antibodies were partially purified using conventional precipitation method and used as antigen for immunizing a BALB/c mouse. Splenocytes were fused with myeloma cells and a hybridoma clone secreting a desirable secondary antibody (mAb#2-16) was established. The secondary antibody bound specifically to emu-derived IgY, distinguishing IgYs from chicken, duck, ostrich, quail, and turkey, as well as human IgGs. Affinity columns immobilizing the mAb#2-16 antibodies enabled purification of emu IgY fractions from sera and egg yolks via simple protocols, with which we succeeded in producing IgYs specific to the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein with a practical binding ability. We expect that the presented purification method, and the secondary antibody produced in this study, will facilitate the utilization of emus as a novel source of therapeutic and diagnostic antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a emu | |
| 650 | 4 | |a immunoglobulin Y (IgY) | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a purification | |
| 650 | 4 | |a secondary antibody | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a IgY |2 NLM | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 700 | 1 | |a Ohta, Kiyoe |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Norihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Izumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kiguchi, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Nanbo, Asuka |e verfasserin |4 aut | |
| 700 | 1 | |a Oh-Oka, Hirozo |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kawata, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujisawa, Hirotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Mitsuhiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biological & pharmaceutical bulletin |d 1997 |g 45(2022), 8 vom: 01., Seite 1022-1026 |w (DE-627)NLM074696084 |x 1347-5215 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:8 |g day:01 |g pages:1022-1026 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1248/bpb.b22-00220 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 8 |b 01 |h 1022-1026 | ||